CY1119626T1 - Βελτιστοποιηση διαλυτοτητας των ανοσοσυνδετικων μοριων - Google Patents
Βελτιστοποιηση διαλυτοτητας των ανοσοσυνδετικων μοριωνInfo
- Publication number
- CY1119626T1 CY1119626T1 CY20171100670T CY171100670T CY1119626T1 CY 1119626 T1 CY1119626 T1 CY 1119626T1 CY 20171100670 T CY20171100670 T CY 20171100670T CY 171100670 T CY171100670 T CY 171100670T CY 1119626 T1 CY1119626 T1 CY 1119626T1
- Authority
- CY
- Cyprus
- Prior art keywords
- solubility
- scfvs
- optimizing
- provides methods
- provides
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 3
- 206010061598 Immunodeficiency Diseases 0.000 abstract 1
- 230000003321 amplification Effects 0.000 abstract 1
- 238000004458 analytical method Methods 0.000 abstract 1
- 238000003119 immunoblot Methods 0.000 abstract 1
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 1
- 238000012163 sequencing technique Methods 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
Η εφεύρεση παρέχει μεθόδους χρήσης αναλύσεων των αλληλουχιών και ορθολογικών στρατηγικών βελτίωσης της διαλυτότητας των ανοσοσυνδετικών μορίων, και ειδικότερα των αντισωμάτων μονής αλύσου (scFvs). Η εφεύρεση παρέχει μεθόδους τροποποίησης των ανοσοσυνδετικών μορίων και ειδικότερα των scFvs, εφαρμόζοντας μια ή περισσότερες αντικαταστάσεις από υδρόφιλα κατάλοιπα, τα οποία αναγνωρίζονται από την ανάλυση συγκεκριμένων, σταθερών αλληλουχιών scFvs από βάσεις δεδομένων. Η εφεύρεση παρέχει επίσης ανοσοσυνδετικά μόρια με βελτιστοποιημένη διαλυτότητα, τα οποία παρασκευάζονται σύμφωνα με τις μεθόδους ενίσχυσης της εφεύρεσης.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7569208P | 2008-06-25 | 2008-06-25 | |
| PCT/CH2009/000221 WO2009155725A1 (en) | 2008-06-25 | 2009-06-25 | Solubility optimization of immunobinders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119626T1 true CY1119626T1 (el) | 2018-04-04 |
Family
ID=41228195
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100670T CY1119626T1 (el) | 2008-06-25 | 2017-06-22 | Βελτιστοποιηση διαλυτοτητας των ανοσοσυνδετικων μοριων |
| CY20211100832T CY1124644T1 (el) | 2008-06-25 | 2021-09-22 | Βελτιστοποιηση διαλυτοτητας των ανοσοσυνδετικων μοριων |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100832T CY1124644T1 (el) | 2008-06-25 | 2021-09-22 | Βελτιστοποιηση διαλυτοτητας των ανοσοσυνδετικων μοριων |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9556265B2 (el) |
| EP (2) | EP2307455B1 (el) |
| JP (3) | JP5745720B2 (el) |
| KR (2) | KR101790567B1 (el) |
| CN (2) | CN105418763A (el) |
| AU (1) | AU2009264566B2 (el) |
| BR (1) | BRPI0914666A2 (el) |
| CA (1) | CA2728829C (el) |
| CY (2) | CY1119626T1 (el) |
| DK (2) | DK3241843T3 (el) |
| ES (2) | ES2884117T3 (el) |
| HR (2) | HRP20171250T1 (el) |
| HU (2) | HUE056090T2 (el) |
| LT (2) | LT3241843T (el) |
| MX (2) | MX2011000074A (el) |
| PL (2) | PL3241843T3 (el) |
| PT (2) | PT3241843T (el) |
| RU (3) | RU2514658C2 (el) |
| SI (2) | SI2307455T1 (el) |
| WO (1) | WO2009155725A1 (el) |
| ZA (1) | ZA201008595B (el) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3722310T (lt) | 2008-06-25 | 2024-12-27 | Novartis Ag | Stabilūs ir tirpūs antikūnai, slopinantys vegf |
| TR201808591T4 (tr) | 2008-06-25 | 2018-07-23 | Esbatech Alcon Biomed Res Unit | Bir evrensel bir antikor iskeleti kullanılarak tavşan antikorların insanlaştırılması. |
| ES2884117T3 (es) | 2008-06-25 | 2021-12-10 | Novartis Ag | Optimización de la solubilidad de inmunoaglutinantes |
| RU2567100C2 (ru) | 2008-06-25 | 2015-10-27 | ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи | СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα |
| US8399625B1 (en) | 2009-06-25 | 2013-03-19 | ESBATech, an Alcon Biomedical Research Unit, LLC | Acceptor framework for CDR grafting |
| BR112012017051A2 (pt) * | 2009-12-23 | 2017-12-05 | Esbatech Alcon Biomed Res Unit | método para diminuir a imunogenicidade |
| AU2014262201B2 (en) * | 2009-12-23 | 2016-09-15 | Novartis Ag | Method for decreasing immunogenicity |
| AR083495A1 (es) | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles |
| EP2670778A1 (en) * | 2011-02-02 | 2013-12-11 | Glaxo Group Limited | Novel antigen binding proteins |
| RU2711118C2 (ru) | 2012-11-05 | 2020-01-15 | Деленекс Терапьютикс Аг | Элементы, связывающиеся с ил-1 бета |
| EP2931750B8 (en) | 2012-12-17 | 2021-11-03 | Cell Medica Inc. | Antibodies against il-1 beta |
| JP2016506974A (ja) * | 2013-02-15 | 2016-03-07 | エスバテック − ア ノバルティスカンパニー エルエルシー | Ｃｄｒグラフトのためのアクセプターフレームワーク |
| CN104884471A (zh) * | 2013-02-20 | 2015-09-02 | 艾斯巴技术-诺华有限责任公司 | 用于cdr移植的受体框架 |
| PE20160192A1 (es) | 2013-08-12 | 2016-04-27 | Genentech Inc | Composiciones y metodo para tratar condiciones asociadas con el complemento |
| JP6580570B2 (ja) * | 2013-09-06 | 2019-09-25 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗体安定性を向上させるための方法 |
| CN106536561A (zh) | 2014-05-01 | 2017-03-22 | 豪夫迈·罗氏有限公司 | 抗‑因子d抗体变体及其用途 |
| EP3159346B1 (en) * | 2015-10-21 | 2018-07-04 | Trinseo Europe GmbH | Aminosilane-functionalized dienes for use in functionalization of elastomeric polymers |
| CN108699153B (zh) | 2016-02-25 | 2022-09-23 | 细胞医学瑞士公司 | Pd-l1的结合成员 |
| CA3208905A1 (en) | 2021-02-12 | 2022-08-18 | Boehringer Ingelheim International Gmbh | Complement c3 antigen binding proteins |
| MX2023010541A (es) | 2021-03-09 | 2023-11-24 | Cdr Life Ag | Proteinas de union al antigeno del peptido del mhc mage-a4. |
| US20220340894A1 (en) | 2021-03-09 | 2022-10-27 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
| JP2024546875A (ja) | 2021-12-14 | 2024-12-26 | シーディアール－ライフ・アクチェンゲゼルシャフト | 二連型ｍｈｃ標的化ｔ細胞エンゲージャー |
| US12344663B2 (en) | 2021-12-22 | 2025-07-01 | Cdr-Life Ag | Anti-C3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases |
| WO2024056758A1 (en) | 2022-09-14 | 2024-03-21 | Cdr-Life Ag | Mage-a4 peptide dual t cell engagers |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| DK0669836T3 (da) | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom |
| US6740734B1 (en) | 1994-01-14 | 2004-05-25 | Biovitrum Ab | Bacterial receptor structures |
| MX336813B (es) | 1996-02-09 | 2016-02-02 | Abbvie Biotechnology Ltd | Anticuerpos humanos que ligan el tnfa humano. |
| JP2000516452A (ja) | 1996-07-16 | 2000-12-12 | プリュックテュン，アンドレアス | 可溶性が増大した免疫グロブリンスーパーファミリードメインおよびフラグメント |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| ES2301198T3 (es) | 1997-06-12 | 2008-06-16 | Novartis International Pharmaceutical Ltd. | Polipeptidos artificiales de anticuerpos. |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| CN101695574A (zh) | 1998-08-11 | 2010-04-21 | 拜奥根Idec公司 | 包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法 |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| SE9901379D0 (sv) | 1999-04-19 | 1999-04-19 | Pharmacia & Upjohn Ab | Receptor structures |
| US6602977B1 (en) | 1999-04-19 | 2003-08-05 | Biovitrum Ab | Receptor structures |
| US7258986B2 (en) | 1999-12-28 | 2007-08-21 | Esbatech Ag | Intrabodies with defined framework that is stable in a reducing environment and applications thereof |
| ATE419354T1 (de) | 2000-02-25 | 2009-01-15 | Us Gov Health & Human Serv | Scfv-moleküle gegen egfrviii mit verbesserter zytotoxizität und ausbeute, darauf basierte immuntoxine, und verfahren zur deren verwendung |
| DK1332209T3 (da) | 2000-09-08 | 2010-03-29 | Univ Zuerich | Samlinger af repeatproteiner indeholdende repeatmoduler |
| JP4369662B2 (ja) | 2001-04-26 | 2009-11-25 | アビディア インコーポレイテッド | 単量体ドメインのコンビナトリアルライブラリー |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| US6905608B2 (en) | 2002-01-22 | 2005-06-14 | Exergy Technologies Corporation | Advanced electrodeionization for fluid recycling |
| CN103739706B (zh) | 2002-05-22 | 2015-11-18 | 艾斯巴技术-诺华有限责任公司 | 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法 |
| KR20160014775A (ko) * | 2003-05-30 | 2016-02-11 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체를 사용한 치료 |
| AU2003264100A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of a bilin-binding protein with affinity for a given target |
| EP1773872B1 (en) | 2004-05-21 | 2017-03-15 | The Uab Research Foundation | Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof |
| CA2609999C (en) | 2005-06-07 | 2017-05-30 | Esbatech Ag | Stable and soluble antibodies inhibiting tnf.alpha. |
| PT2046382T (pt) | 2006-07-10 | 2016-11-23 | Esbatech Alcon Biomed Res Unit | Anticorpos scfv que atravessam as camadas epitelial e/ou endotelial |
| CN101668771B (zh) | 2007-03-12 | 2013-08-21 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 单链抗体的基于序列的工程改造和最优化 |
| MX2009013327A (es) | 2007-06-25 | 2010-06-02 | Esbatech An Alcon Biomedical R | Ingenieria basada en secuencias y optimizacion de anticuerpos de cadena simple. |
| NZ601946A (en) | 2007-06-25 | 2013-12-20 | Esbatech Alcon Biomed Res Unit | Methods of modifying antibodies, and modified antibodies with improved functional properties |
| ES2884117T3 (es) | 2008-06-25 | 2021-12-10 | Novartis Ag | Optimización de la solubilidad de inmunoaglutinantes |
-
2009
- 2009-06-25 ES ES17161990T patent/ES2884117T3/es active Active
- 2009-06-25 CN CN201511018105.0A patent/CN105418763A/zh active Pending
- 2009-06-25 CN CN200980123815.6A patent/CN102076715B/zh active Active
- 2009-06-25 PL PL17161990T patent/PL3241843T3/pl unknown
- 2009-06-25 SI SI200931674A patent/SI2307455T1/sl unknown
- 2009-06-25 RU RU2011102548/10A patent/RU2514658C2/ru active
- 2009-06-25 EP EP09768694.3A patent/EP2307455B1/en not_active Revoked
- 2009-06-25 EP EP17161990.1A patent/EP3241843B1/en active Active
- 2009-06-25 CA CA2728829A patent/CA2728829C/en active Active
- 2009-06-25 KR KR1020167017202A patent/KR101790567B1/ko active Active
- 2009-06-25 US US13/000,460 patent/US9556265B2/en active Active
- 2009-06-25 HU HUE17161990A patent/HUE056090T2/hu unknown
- 2009-06-25 PL PL09768694T patent/PL2307455T3/pl unknown
- 2009-06-25 PT PT171619901T patent/PT3241843T/pt unknown
- 2009-06-25 WO PCT/CH2009/000221 patent/WO2009155725A1/en active Application Filing
- 2009-06-25 LT LTEP17161990.1T patent/LT3241843T/lt unknown
- 2009-06-25 LT LTEP09768694.3T patent/LT2307455T/lt unknown
- 2009-06-25 JP JP2011515050A patent/JP5745720B2/ja active Active
- 2009-06-25 HR HRP20171250TT patent/HRP20171250T1/hr unknown
- 2009-06-25 ES ES09768694.3T patent/ES2629345T3/es active Active
- 2009-06-25 PT PT97686943T patent/PT2307455T/pt unknown
- 2009-06-25 AU AU2009264566A patent/AU2009264566B2/en active Active
- 2009-06-25 MX MX2011000074A patent/MX2011000074A/es active IP Right Grant
- 2009-06-25 KR KR1020117001959A patent/KR101650165B1/ko active Active
- 2009-06-25 DK DK17161990.1T patent/DK3241843T3/da active
- 2009-06-25 SI SI200932137T patent/SI3241843T1/sl unknown
- 2009-06-25 HU HUE09768694A patent/HUE034827T2/en unknown
- 2009-06-25 DK DK09768694.3T patent/DK2307455T3/en active
- 2009-06-25 BR BRPI0914666A patent/BRPI0914666A2/pt not_active Application Discontinuation
- 2009-06-25 MX MX2013011865A patent/MX346024B/es unknown
-
2010
- 2010-11-30 ZA ZA2010/08595A patent/ZA201008595B/en unknown
-
2014
- 2014-02-10 RU RU2014104577A patent/RU2653441C2/ru active
- 2014-03-18 JP JP2014054856A patent/JP2014111667A/ja active Pending
-
2016
- 2016-04-06 JP JP2016076318A patent/JP2016128517A/ja active Pending
- 2016-12-14 US US15/378,649 patent/US10221237B2/en active Active
-
2017
- 2017-06-22 CY CY20171100670T patent/CY1119626T1/el unknown
-
2018
- 2018-04-05 RU RU2018112257A patent/RU2018112257A/ru not_active Application Discontinuation
-
2019
- 2019-02-05 US US16/267,460 patent/US11046757B2/en active Active
-
2021
- 2021-08-25 HR HRP20211356TT patent/HRP20211356T1/hr unknown
- 2021-09-22 CY CY20211100832T patent/CY1124644T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119626T1 (el) | Βελτιστοποιηση διαλυτοτητας των ανοσοσυνδετικων μοριων | |
| CY1126083T1 (el) | Μοντελα τρωκτικων και θεραπευτικα μορια | |
| CY1119893T1 (el) | Προϊοντα συζευξης cc-1065 αναλογων και διλειτουργικων συνδετων | |
| CY1121672T1 (el) | Αντισωματα που προσδενουν τα il-17a και il-17f | |
| CY1125133T1 (el) | Πρωτεϊνες συνδεσης αντιγονου υποδοχεα a il-17 | |
| CY1123932T1 (el) | Δομες πολυειδικου αντισωματος | |
| CY1123831T1 (el) | Γενετικως τροποποιημενοι ποντικοι υποδοχεα τ κυτταρων | |
| CY1122036T1 (el) | Μη ανθρωπινα ζωα που εκφραζουν αντισωματα τα οποια εχουν μια κοινη ελαφρια αλυσιδα | |
| CY1120651T1 (el) | Παραγωγα λακταμης χρησιμα ως αναστολεις μεταλλαγμενης idh1 | |
| CY1119994T1 (el) | Συνθεσεις και μεθοδοι για αυξηση της μυϊκης μαζας και της μυϊκης δυναμης ανταγωνιζοντας ειδικα ton gdf8 και/ή την ακτιβινη α | |
| CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
| CY1121632T1 (el) | Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης | |
| CY1117859T1 (el) | Αντισωματα και ανοσοσυζευγματα anti-cd79b και μεθοδοι χρησης | |
| CY1117767T1 (el) | Rsv-ειδικα προσδενομενα μορια και μεσα για την παραγωγη αυτων | |
| CY1117650T1 (el) | Νεες ανοσοενισχυτικες συνθεσεις | |
| CY1117563T1 (el) | Αντισωματα κατα her3 και χρησεις αυτων | |
| CY1121046T1 (el) | Στοχευση toy abcb5 για θεραπεια του καρκινου | |
| AR110526A1 (es) | Anticuerpos anti-ox40 y sus usos en el tratamiento del cáncer | |
| DK201100184U1 (da) | Method for immunizing an avian species | |
| CY1115700T1 (el) | Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης | |
| CY1116279T1 (el) | Η χρηση των ανθρωπινων κυτταρων προελευσης μυελογενους λευχαιμιας για την εκφραση αντισωματων | |
| UA115321C2 (uk) | Спосіб та комплект для аналізу ahasl генів у рослин | |
| EA201290638A1 (ru) | Соединения и способы | |
| CY1114661T1 (el) | Ταυτοποιηση αντιγονων που σχετιζονται με ογκο για διαγνωση και θεραπεια | |
| TR201815882T4 (tr) | Tal efektörü aracılı dna modifikasyonu. |